Why Is Robotic Surgery-Focused Penny Stock Asensus Surgical Trading Higher On Friday?
Why Is Robotic Surgery-Focused Penny Stock Asensus Surgical Trading Higher On Friday?
On Friday, KARL STORZ Endoscopy-America, Inc. agreed to acquire Asensus Surgical Inc. (NYSE:ASXC) for $0.35 per share in cash.
周五，KARL STORZ内窥镜设备-美国公司同意收购Asensus Surgical Inc.（纽交所：ASXC）的现金股票每股0.35美元。
KARL STORZ is a wholly-owned direct subsidiary of KARL STORZ SE & Co. KG, an independent, family-owned global medical technology company based in Germany.
KARL STORZ是KARL STORZ SE＆Co. KG的全资直接子公司，后者是一家独立的，家族式的总部位于德国的全球医疗科技公司。
The purchase price represents a premium of approximately 67% based on the per-share closing price of the Asensus common stock on the NYSE American on April 2 and a premium of approximately 52% to the closing price of the common stock on the last trading day prior to the date of this announcement.
购买价格基于Asensus普通股在4月2日纽交所美国交易日收盘价的每股收盘价，代表了约67％的溢价，并且基于本公告日期之前最后一个交易日普通股的收盘价的溢价约为52％。
In April, Asensus entered into a non-binding letter of intent with KARL STORZ to engage in diligence and negotiations.
4月，Asensus与KARL STORZ签署了一份非约束性意向书进行尽职调查和谈判。
Asensus' Board has unanimously approved the transaction of Directors.
Asensus的董事会一致批准了本次交易。
The transaction would enhance KARL STORZ's portfolio and market presence, strengthening KARL STORZ's position in the robotic surgical market, particularly with the development of the next-generation LUNA system.
该交易将增强KARL STORZ的组合和市场存在感，增强KARL STORZ在机器人手术市场的地位，特别是在开发下一代LUNA系统方面。
The transaction is anticipated to close during the third quarter of 2024.
预计该交易将在2024年第三季度结束。
Upon completion of the transaction, Asensus Surgical will become a subsidiary of KARL STORZ Endoscopy-America and no longer be publicly listed or traded on the NYSE American Exchange.
交易完成后，Asensus Surgical将成为KARL STORZ内窥镜设备-美国的子公司，不再在纽交所美国交易所公开上市或交易。
In April, Asensus secured a loan of up to $20 million from KARL STORZ to support operations during the exclusivity period and potential transaction process.
四月，Asensus从KARL STORZ获得了高达2000万美元的贷款，以支持独家期内的营运和潜在交易进程。
This loan will provide up to $10 million of liquidity during exclusivity. The medical device company said that if a definitive merger agreement is successfully negotiated and executed, additional funding in an aggregate amount of up to $10 million will be available under the loan.
这项贷款将在独家期内提供多达1000万美元的流动资金。该医疗器械公司表示，如果成功谈判并执行明确的合并协议，该贷款将提供多达1000万美元的额外资金。
Asensus generated first-quarter 2024 revenues of $1.1 million.
Asensus在2024年第一季度实现了110万美元的收入。
Price Action: ASXC shares are up 41.40% at $0.33 at the last check on Friday.
股票价格：截至上周五，ASXC股票上涨了41.40％，至0.33美元/股。